ABSTRACT
OBJECTIVE:To explore the clinical efficacy and safety of cetuximab combined with NP regimen and radiotherapy in the treatment of advanced non-small cell lung cancer(NSCLC). METHODS:76 cases of advanced NSCLC were selected and randomly divided into control group and observation group according to different therapy methods,with 38 cases in each group. Control group received NP regimen(cisplatin 25 mg/m2+navelbine 12.5 mg/m2)+thoracic IMRT;observation group was additional-ly given cetuximab 400 mg/m2(first day),with maintenance dose of 250 mg/m2 weekly and last for 13 weeks. Short-term efficacy, survival situation were compared between 2 groups as well as the levels of T lymphocyte,Th1,Th2,immuneglobulin(Ig) and complement. The occurrence of ADR was recorded. RESULTS:The total effective rate of observation group was 86.84%,which was significantly higher than that of control group(65.79%),with statistical significance(P0.05). There was no statistical significance in the incidence of ADR between 2 groups (P>0.05). CONCLUSIONS:Cetuximab combined with NP regimen and radiotherapy can improve clinical efficacy of advanced NSCLC,improve survival quality,prolong survival time and promote the recovery of Ig,complement and T lymphocyte,with good safety.